ANALYSIS OF THE EFFECTIVENESS OF THE PROLONGED ACTION OF THE DRUG "INTERLEUKIN-1B", AIMED AT A LOCAL DECREASE IN THE CYTOKINE CASCADE IN PERIODONTAL TISSUES IN PATIENTS WITH BRONCHIAL ASTHMA

The study involved 63 patients of the pulmonology department with a history of concomitant diseases of bronchial asthma (BA). The patients were divided into the main group 1 (27 patients who under went treatment of periodontal diseases according to the standard treatment protocol) and the main group 2 (36 patients who, in addition to standard therapy for periodontal diseases, were prescribed a course of Interleukin 1b). The control group consisted of 19 conditionally healthy people with no history of somatic pathology. According to the criteria from the national program “Bronchial Asthma”, 27 (27 %) patients were diagnosed with a mild form of BA, 19 (52 %) - with a moderate form, and 9 (20,1 %) – with a severe form of BA. The selection of patients was carried out on the basis of inclusion, non-inclusion and exclusion criteria in the study. The effectiveness of the therapy was assessed by the hygiene index (J.C. Green, J.K. Vermillion (OHI-S)), the papillary-marginal-alveolar index (PMA) in the Parma modification. The level of destructive processes in the bone tissue was assessed using sighting radiographs and orthopantomograms. The quality of the treatment was assessed after 3 weeks, 4 months and then 6 months from the start of treatment.